Ocena skuteczności terapeutycznej preparatu Dentosept A® (Phytopharm Klęka S.A.) oraz Sachol® (Jelfa S.A.) u pacjentów z aftowym zapaleniem błony śluzowej jamy ustnej

*Aleksandra Sender-Janeczek¹, Magdalena Kwiatkowska²

Summary
Introduction. Recurrent aphthous stomatitis (RAS) is the most common non-infectious oral mucosal lesions worldwide. Because there is still no specific etiological factors, the main goal of the therapy is to eliminate the predisposing factors and reduce the time of its occurrence.
Aim. The aim of the study was the evaluation of therapeutic efficacy of the Dentosept A® (Phytopharm Klęka S.A.) and Sachol® (Jelfa S.A.) in patients with aphthous stomatitis.
Material and methods. The study involved 70 patients with recurrent aphthous stomatitis, aged from 21 to 80 years. In group I, patients were applied Dentosept A® and the group II was applied Sachol® on the changes in the oral mucosa. Clinical examination of the oral mucosa were made before application of the products and control examination were made at 4 and 7 days of use the product.
Results. After applying both Dentosept A® and Sachol® achieved a significant improvement in the clinical condition of the treated changes in the oral mucosa, the differences between the groups were not statistically significant.
Conclusions. It seems that Dentosept A® and also Sachol® can be of significant help in the treatment of erosions and ulcers of the oral mucosa, thereby contributing to a faster healing of lesions.

To jest tylko fragment artykułu. Aby przeczytać całość, przejdź do Czytelni medycznej.